<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药魔方Info | wechat-feeds</title><link>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</link><description>传递医药信息，分享资源数据！充电5分钟，吹牛2小时！</description><managingEditor> (hellodword)</managingEditor><pubDate>Fri, 05 Feb 2021 20:21:09 +0800</pubDate><image><url>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</url><title>医药魔方Info | wechat-feeds</title><link>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>罗氏2020年财报：Tecentriq增长55%！老三驾马车交棒，前沿创新疗法上位</title><link>https://mp.weixin.qq.com/s/0nfQRUtBj1WU2eE8k6D9yQ</link><description></description><content:encoded><![CDATA[罗氏2020年财报：Tecentriq增长55%！老三驾马车交棒，前沿创新疗法上位]]></content:encoded><pubDate>Fri, 05 Feb 2021 18:29:47 +0800</pubDate></item><item><title>吉利德2020年财报：细胞疗法收入增长33%！瑞德西韦大卖28.11亿美元</title><link>https://mp.weixin.qq.com/s/UeoI4N28KUceaEeCYhNcIw</link><description></description><content:encoded><![CDATA[吉利德2020年财报：细胞疗法收入增长33%！瑞德西韦大卖28.11亿美元]]></content:encoded><pubDate>Fri, 05 Feb 2021 18:29:47 +0800</pubDate></item><item><title>默沙东2020年财报：Keytruda销售额143.8亿美元！行业大佬CEO卸任</title><link>https://mp.weixin.qq.com/s/rd6MGQu_eucrzg_98nrCAg</link><description></description><content:encoded><![CDATA[默沙东2020年财报：Keytruda销售额143.8亿美元！行业大佬CEO卸任]]></content:encoded><pubDate>Fri, 05 Feb 2021 18:29:47 +0800</pubDate></item><item><title>艾伯维2020年财报：Humira再度逼近200亿美元！精神分裂症新药Vraylar惊艳</title><link>https://mp.weixin.qq.com/s/oUKyTKa0kbMGg4ITHawsZg</link><description></description><content:encoded><![CDATA[艾伯维2020年财报：Humira再度逼近200亿美元！精神分裂症新药Vraylar惊艳]]></content:encoded><pubDate>Fri, 05 Feb 2021 18:29:47 +0800</pubDate></item><item><title>Jazz制药72亿美元收购大麻素领军企业GW制药</title><link>https://mp.weixin.qq.com/s/vToNC5e1sd8TVSkNK1G4-Q</link><description></description><content:encoded><![CDATA[Jazz制药72亿美元收购大麻素领军企业GW制药]]></content:encoded><pubDate>Fri, 05 Feb 2021 18:29:47 +0800</pubDate></item><item><title>国家药监局：2020年共批准54个新冠病毒检测试剂，26个创新医疗器械产品</title><link>https://mp.weixin.qq.com/s/KQSl02xNANiA3dofW2yH3g</link><description></description><content:encoded><![CDATA[国家药监局：2020年共批准54个新冠病毒检测试剂，26个创新医疗器械产品]]></content:encoded><pubDate>Fri, 05 Feb 2021 18:29:47 +0800</pubDate></item><item><title>德琪医药SINE​抑制剂 selinexor 上市申请拟纳入优先审评，治疗多发性骨髓瘤</title><link>https://mp.weixin.qq.com/s/3K0jF2EQmCQMuhpU0YYe-Q</link><description></description><content:encoded><![CDATA[德琪医药SINE​抑制剂 selinexor 上市申请拟纳入优先审评，治疗多发性骨髓瘤]]></content:encoded><pubDate>Fri, 05 Feb 2021 18:29:47 +0800</pubDate></item><item><title>临床急需AML新药吉瑞替尼获批上市！靶向FLT3突变利剑出鞘</title><link>https://mp.weixin.qq.com/s/lac5zqylr0BwDdNLLmQHrA</link><description></description><content:encoded><![CDATA[临床急需AML新药吉瑞替尼获批上市！靶向FLT3突变利剑出鞘]]></content:encoded><pubDate>Thu, 04 Feb 2021 15:08:27 +0800</pubDate></item><item><title>GSK 2020年财报：全球首个BCMA靶向疗法上市开门红！终止OX40、LAG-3靶点项目开发</title><link>https://mp.weixin.qq.com/s/8MKw6_n8VyepAnPlCM6Gag</link><description></description><content:encoded><![CDATA[GSK 2020年财报：全球首个BCMA靶向疗法上市开门红！终止OX40、LAG-3靶点项目开发]]></content:encoded><pubDate>Thu, 04 Feb 2021 15:08:27 +0800</pubDate></item><item><title>默克MET抑制剂获FDA批准上市，治疗NSCLC</title><link>https://mp.weixin.qq.com/s/0r6NvU1fxjD07KaO0TPDtQ</link><description></description><content:encoded><![CDATA[默克MET抑制剂获FDA批准上市，治疗NSCLC]]></content:encoded><pubDate>Thu, 04 Feb 2021 15:08:27 +0800</pubDate></item><item><title>2款进口新药提交上市申请！来自安进、拜耳</title><link>https://mp.weixin.qq.com/s/81WVLxHTaA6o1P5wg9fxWQ</link><description></description><content:encoded><![CDATA[2款进口新药提交上市申请！来自安进、拜耳]]></content:encoded><pubDate>Thu, 04 Feb 2021 15:08:27 +0800</pubDate></item><item><title>BMS地中海贫血新药Luspatercept上市申请获CDE优先审评</title><link>https://mp.weixin.qq.com/s/fK04CNufnCDccPwb2uCRAA</link><description></description><content:encoded><![CDATA[BMS地中海贫血新药Luspatercept上市申请获CDE优先审评]]></content:encoded><pubDate>Thu, 04 Feb 2021 15:08:27 +0800</pubDate></item><item><title>第四批国家集采报价及中标结果</title><link>https://mp.weixin.qq.com/s/1q_bAQ82jdjM7v-aS5wBZw</link><description></description><content:encoded><![CDATA[第四批国家集采报价及中标结果]]></content:encoded><pubDate>Wed, 03 Feb 2021 16:05:42 +0800</pubDate></item><item><title>阿斯利康「达格列净」心衰适应症在华获批</title><link>https://mp.weixin.qq.com/s/uk9KSN_dUhFcq8DoBg9N-Q</link><description></description><content:encoded><![CDATA[阿斯利康「达格列净」心衰适应症在华获批]]></content:encoded><pubDate>Wed, 03 Feb 2021 16:05:42 +0800</pubDate></item><item><title>信迪利单抗第2项适应症获批：一线治疗非鳞状NSCLC</title><link>https://mp.weixin.qq.com/s/-zNvE5BiY8d5hMX5zxBUFA</link><description></description><content:encoded><![CDATA[信迪利单抗第2项适应症获批：一线治疗非鳞状NSCLC]]></content:encoded><pubDate>Wed, 03 Feb 2021 16:05:42 +0800</pubDate></item><item><title>拜耳雄激素受体抑制剂darolutamide在华获批上市</title><link>https://mp.weixin.qq.com/s/Y2vdFhFdGxdc_pSJKHnsZQ</link><description></description><content:encoded><![CDATA[拜耳雄激素受体抑制剂darolutamide在华获批上市]]></content:encoded><pubDate>Wed, 03 Feb 2021 16:05:42 +0800</pubDate></item><item><title>最终版！227个第四批带量采购产品竞标信息</title><link>https://mp.weixin.qq.com/s/31hRVOWN9yK2HkKJjlrgrg</link><description></description><content:encoded><![CDATA[最终版！227个第四批带量采购产品竞标信息]]></content:encoded><pubDate>Tue, 02 Feb 2021 18:13:29 +0800</pubDate></item><item><title>百济神州注射用紫杉醇（白蛋白结合型）胰腺癌适应症即将获批</title><link>https://mp.weixin.qq.com/s/X4stbS0mFnhSt01vTCvA8Q</link><description></description><content:encoded><![CDATA[百济神州注射用紫杉醇（白蛋白结合型）胰腺癌适应症即将获批]]></content:encoded><pubDate>Tue, 02 Feb 2021 18:13:29 +0800</pubDate></item><item><title>正大天晴艾司奥美拉唑镁肠溶胶囊、恩格列净片搭上集采末班车，安罗替尼新适应症获批</title><link>https://mp.weixin.qq.com/s/wOhSjuEYxBDWejtDQT1bLg</link><description></description><content:encoded><![CDATA[正大天晴艾司奥美拉唑镁肠溶胶囊、恩格列净片搭上集采末班车，安罗替尼新适应症获批]]></content:encoded><pubDate>Tue, 02 Feb 2021 18:13:29 +0800</pubDate></item><item><title>江苏省未挂网产品，无国家医保药品编码将不能申报阳光采购</title><link>https://mp.weixin.qq.com/s/yVqrGpN73ul-HG-_e8Xbqw</link><description></description><content:encoded><![CDATA[江苏省未挂网产品，无国家医保药品编码将不能申报阳光采购]]></content:encoded><pubDate>Tue, 02 Feb 2021 18:13:29 +0800</pubDate></item></channel></rss>